Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy?

被引：25

作者：

Insa, Amelia ^{[1
]}

Martin-Martorell, Paloma ^{[1
]}

Di Liello, Raimondo ^{[2
]}

Fasano, Morena ^{[2
]}

Martini, Giulia ^{[2
]}

Napolitano, Stefania ^{[2
]}

Vicidomini, Giovanni ^{[3
]}

Cappabianca, Salvatore ^{[4
]}

Franco, Renato ^{[5
]}

Morgillo, Floriana ^{[2
]}

Della Corte, Carminia Maria ^{[2
]}

机构：

[1] Hosp Clin Univ Valencia, Med Oncol Dept, Valencia 46010, Spain

[2] Univ Campania Luigi Vanvitelli, Dept Precis Med, Med Oncol, Via Sergio Pansini 5, I-80131 Naples, Italy

[3] Univ Campania Luigi Vanvitelli, Dept Translat Med Sci, Thorac Surg Unit, I-80131 Naples, Italy

[4] Univ Campania Luigi Vanvitelli, Radiol, Dept Precis Med, I-80131 Naples, Italy

[5] Univ Campania Luigi Vanvitelli, Dept Expt Med, Pathol Unit, I-80131 Naples, Italy

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2022年 / 169卷

关键词：

Immunotherapy; Chemotherapy; Second line therapy; NSCLC; ICI resistance; CELL LUNG-CANCER; IMMUNE CHECKPOINT INHIBITORS; NIVOLUMAB PLUS IPILIMUMAB; PHASE-III; PD-L1; EXPRESSION; OPEN-LABEL; CHEMOTHERAPY CHEMO; 1ST-LINE NIVOLUMAB; PATIENTS PTS; PEMBROLIZUMAB;

D O I：

10.1016/j.critrevonc.2021.103538

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cancer immunotherapy has produced an unprecedented durable response rate, thus shifting from traditional doublet chemotherapy to immunotherapy-based treatments with and without chemotherapy as the first line strategies for advanced non-small cell lung cancer patients without a molecular driver. However, the majority of patients do not benefit from the treatment or may relapse after a period of response. As few treatment options are available after failure of cancer immunotherapy, including the combination of chemotherapy and antiangiogenic drugs, a better understanding of the mechanisms limiting cancer immunotherapy may be of help in the definition of the best second line. Whereas only retrospective data support an immunotherapy rechallenge approach, new combination strategies including immunotherapy and cell-signaling inhibitors or double immunotherapy represent the newest and most promising strategy to overcome primary or acquired resistance to first line immunotherapy.

引用

页数：10

共 88 条

[1] Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis [J].

Abu-Sbeih, Hamzah ;

Ali, Faisal S. ;

Naqash, Abdul Rafeh ;

Owen, Dwight H. ;

Patel, Sandipkumar ;

Otterson, Gregory A. ;

Kendra, Kari ;

Ricciuti, Biagio ;

Chiari, Rita ;

De Giglio, Andrea ;

Sleiman, Joseph ;

Funchain, Pauline ;

Wills, Beatriz ;

Zhang, Jiajia ;

Naidoo, Jarushka ;

Philpott, Jessica ;

Gao, Jianjun ;

Subudhi, Sumit K. ;

Wang, Yinghong .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (30) :2738-+

[2] Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression [J].

Aguilar, E. J. ;

Ricciuti, B. ;

Gainor, J. F. ;

Kehl, K. L. ;

Kravets, S. ;

Dahlberg, S. ;

Nishino, M. ;

Sholl, L. M. ;

Adeni, A. ;

Subegdjo, S. ;

Khosrowjerdi, S. ;

Peterson, R. M. ;

Digumarthy, S. ;

Liu, C. ;

Sauter, J. ;

Rizvi, H. ;

Arbour, K. C. ;

Carter, B. W. ;

Heymach, J. V. ;

Altan, M. ;

Hellmann, M. D. ;

Awad, M. M. .

ANNALS OF ONCOLOGY, 2019, 30 (10) :1653-1659

[3] Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer The PROLUNG Phase 2 Randomized Clinical Trial [J].

Arrieta, Oscar ;

Barron, Feliciano ;

Ramirez-Tirado, Laura Alejandra ;

Zatarain-Barron, Zyanya Lucia ;

Cardona, Andres F. ;

Diaz-Garcia, Diego ;

Yamamoto Ramos, Masao ;

Mota-Vega, Beatriz ;

Carmona, Amir ;

Peralta alvarez, Marco Polo ;

Bautista, Yolanda ;

Aldaco, Fernando ;

Gerson, Raquel ;

Rolfo, Christian ;

Rosell, Rafael .

JAMA ONCOLOGY, 2020, 6 (06) :856-864

[4] IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade [J].

Ayers, Mark ;

Lunceford, Jared ;

Nebozhyn, Michael ;

Murphy, Erin ;

Loboda, Andrey ;

Kaufman, David R. ;

Albright, Andrew ;

Cheng, Jonathan D. ;

Kang, S. Peter ;

Shankaran, Veena ;

Piha-Paul, Sarina A. ;

Yearley, Jennifer ;

Seiwert, Tanguy Y. ;

Ribas, Antoni ;

McClanahan, Terrill K. .

JOURNAL OF CLINICAL INVESTIGATION, 2017, 127 (08) :2930-2940

[5] STING: infection, inflammation and cancer [J].

Barber, Glen N. .

NATURE REVIEWS IMMUNOLOGY, 2015, 15 (12) :760-770

[6]

Barlesi F., 2018, Ann. Oncol, V29, pVIII743, DOI DOI 10.1093/ANNONC/MDY424.066

[7] Novel non-nucleotidic STING agonists for cancer immunotherapy [J].

Berger, Gilles ;

Lawler, Sean E. .

FUTURE MEDICINAL CHEMISTRY, 2018, 10 (24) :2767-2770

[8] Effect of a novel IL-2 cytokine immune agonist (NKTR-214) on proliferating CD8+T cells and PD-1 expression on immune cells in the tumor microenvironment in patients with prior checkpoint therapy. [J].

Bernatchez, Chantale ;

Haymaker, Cara L. ;

Hurwitz, Michael E. ;

Kluger, Harriet M. ;

Tetzlaff, Michael T. ;

Jackson, Natalie ;

Gergel, Ivan ;

Tagliaferri, Mary Ann ;

Zalevsky, Jonathan ;

Hoch, Ute ;

Fanton, Christie ;

Iacucci, Ernesto ;

Aung, Sandra ;

Imperiale, Michael ;

Liao, Ej ;

Bentebibel, Salah E. ;

Tannir, Nizar M. ;

Hwu, Patrick ;

Sznol, Mario ;

Diab, Adi .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

[9] KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50% [J].

Brahmer, J. R. ;

Rodriguez-Abreu, D. ;

Robinson, A. G. ;

Hui, R. ;

Csoszi, T. ;

Fulop, A. ;

Gottfried, M. ;

Peled, N. ;

Tafreshi, A. ;

Cuffe, S. ;

O'Brien, M. ;

Rao, S. ;

Hotta, K. ;

Leal, T. A. ;

Riess, J. W. ;

Jensen, E. ;

Zhao, B. ;

Pietanza, M. C. ;

Reck, M. .

ANNALS OF ONCOLOGY, 2020, 31 :S1181-S1182

[10] Long-term survival outcomes with nivolumab (NIVO) in pts with previously treated advanced non-small cell lung cancer (NSCLC): Impact of early disease control and response [J].

Brahmer, Julie ;

Borghaei, Hossein ;

Ramalingam, Suresh S. ;

Horn, Leora ;

Holgado, Esther ;

Pluzanski, Adam ;

Burgio, Marco A. ;

Garassino, Marina ;

Chow, Laura Q. ;

Gettinger, Scott ;

Crino, Lucio ;

Planchard, David ;

Butts, Charles ;

Drilon, Alexander ;

Wojcik-Tomaszewska, Joanna ;

Otterson, Gregory ;

Hayreh, Vinny ;

Li, Ang ;

Penrod, John R. ;

Antonia, Scott J. .

CANCER RESEARCH, 2019, 79 (13)

← 1 2 3 4 5 6 7 8 9 →